We believe this study is fatally flawed: “Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis”.
This is an Indian study about the use of hydroxychloroquine for infection prevention against COVID-19. This study has not released any official data yet.
Asian countries overall have fared better in controlling Covid-19, with lower mortality which is due to demographics and use of HCQ.
A Belgian study has just been published, on 8,000 patients, and concludes that hydroxychloroquine reduces mortality by 30%
HCQ and AZI are safe in haemodialysis patients at these doses, and HCQ concentrations were not correlated with side effects.
In this study, SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization.
Our study, including a large sample of patients hospitalized with COVID-19 in Italy, shows HCQ use had a 30% reduction of overall in-hospital mortality.
HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Our data doesn’t discourage use of HCQ in inpatients with COVID-19.
This Multicenter Study shows that the risk of death is 30% lower for coronavirus patients treated with hydroxychloroquine.
Corticosteroid treatment didn’t correlate with death in our model whereas both hydroxychloroquine and azithromycin correlated with a lower mortality rate.
Indeed, following bivariate analysis, hydroxychloroquine/azithromycin treatment was associated with a lower rate of ICU admission (P=0.008).
This data states that early care of COVID-19 patients at retirement homes can be effective in saving lives when treated with hydroxychloroquine.
Hydroxychloroquine for COVID patients in moderate cases within the recommendation and use criteria, is safe, highly tolerable, and with little side effects.
HCQ treatment can reduce systemic inflammation and inhibit the cytokine storm, thus protecting multiple organs from inflammatory injuries.
The evidence shown in this work let us think that Zn(II) indeed may play a role in the viral cell cycle, and zinc ionophores boost zinc’s effects.
Indeed, our study suggests that AZI±HCQ might have impacted COVID-19 outcome in a population of patients, optimal timing of treatment interventions to study
The metabolic inhibitors determine which pathways actively inhibits mitochondrial ATP production with hydroxychloroquine
Under ‘Time to resolution of symptoms’ in this article’s interactive diagram, it states that out of the studies referenced, “Hydroxychloroquine might be the most effective in
Scientists globally are protesting the studies that are biased or cover up the effectiveness of hydroxychloroquine by rendering the results statistically insignificant.
HCQ use significantly reduced the mortality rate, but this association was found only in the lowest cumulative dosage exposure group.
Source: c19 Study A live and ongoing index of study data from around the world documenting the use of hydroxychloroquine in treatment at various stages
In this study of over 6000 hospitalized patients with COVID-19 in the New York City, hydroxychloroquine use was associated with decreased mortality.
Hydroxychloroquine use was associated with decreased mortality.
Our data suggest that chronic treatment with HCQ confer protection against SARS-CoV-2 infection.
No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with hydroxychloroquine and azithromycin. Studies are needed in critical-ill and older patients.
The clinical trials on this list are studying Hydroxychloroquine. All trials on the list are supported by NCI.
Origial Source: FranceSoir In the Recovery and Solidarity clinical trials, it is not excluded that patients died as a result of a therapeutic overdose of
Source: Science Direct Background In our institute in Marseille, France, we initiated early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment
Source: Vanguard Nigeria Preliminary trials on the use of chloroquine and hydroxychloroquine as prophylaxis for COVID-19 in Nigeria has recorded some level of success. The
This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.
Conclusions: In subjects free of COVID-19, we found a small increase in QTc associated with use of chloroquine, but not hydroxychloroquine. We found no increased mortality associated with use of hydroxychloroquine.
None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.
This study focuses on anti-malarial drugs like hydroxychloroquine, which have been seen as the most used treatment for COVID-19
To increase the effectiveness of treatments and results, researchers need to give greater focus, when designing trials and when extrapolating from them.
Scientific evidence also supports the use of CQ and HCQ in the treatment of cancer.
Here, we summarize the results or design of clinical studies recently completed or initiated to evaluate the therapeutic activity of chloroquine derivatives in cancer patients.
The anti-HIV effect of chloroquine/hydroxychloroquine is modest by itself but is additive or synergistic when combined with selected antiretrovirals.
